Skip to main content
Top
Published in: Supportive Care in Cancer 2/2020

01-02-2020 | Prostate Cancer | Original Article

Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results

Authors: Brindha Pillay, Daniel Moon, Denny Meyer, Helen Crowe, Sarah Mann, Nicholas Howard, Addie Wootten, Mark Frydenberg

Published in: Supportive Care in Cancer | Issue 2/2020

Login to get access

Abstract

Purpose

There is little research assessing the impact of providing men with information about prostate cancer (PCa) treatment options at the time of referral for a prostate biopsy. Study objectives were to determine whether receiving an information booklet about PCa treatment options prior to receiving biopsy results was acceptable to patients, and if receiving this information influenced levels of anxiety, depression, distress, and treatment decisional conflict.

Methods

Between June 2016 and September 2017, a randomised block design was used to allocate patients from an Australian urology practice into the intervention or control group. Patients in the intervention group were provided with written information about treatment options for localised PCa prior to their biopsy. Outcome measures including the Distress Thermometer, Generalised Anxiety Disorder-7, Patient Health Questionnaire-9, and Decisional Conflict Scale were completed pre-biopsy and 2–3 weeks post-biopsy. Ninety-eight patients referred for an initial prostate biopsy for an elevated PSA test or suspicious digital rectal exam participated in the study (response rate = 78%).

Results

Multimodal repeated-measures analyses showed no significant differences between control and intervention groups in changes in distress, anxiety, or depression from pre- to post-biopsy, and in decisional conflict post-diagnosis (all p > .05). Thirty-five (87%) patients believed that the resource made it easier to understand subsequent explanation of treatment options, and 51 patients (98%) who received the intervention preferred to be given information at that time.

Conclusions

Providing patients with information about treatment options prior to biopsy did not impact on changes in psychological distress and decisional conflict post-biopsy. However, the majority of patients preferred to be given such information at this time point.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0 cancer incidence and mortality worldwide. IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F (2012) GLOBOCAN 2012 v1.0 cancer incidence and mortality worldwide. IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon
3.
go back to reference Hellenthal N, Ellison L (2008) How patients make treatment choices? Nat Clin Pract Urol 5(8):426–433CrossRefPubMed Hellenthal N, Ellison L (2008) How patients make treatment choices? Nat Clin Pract Urol 5(8):426–433CrossRefPubMed
5.
go back to reference Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW (2006) Why do men choose one treatment over another? A review of patient decision making for localised prostate cancer. Cancer 106(9):1865–1874CrossRefPubMed Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, Lee JW (2006) Why do men choose one treatment over another? A review of patient decision making for localised prostate cancer. Cancer 106(9):1865–1874CrossRefPubMed
8.
go back to reference Chabrera CM, Zabalegui A, Bonet M, Caro M, Areal J, Gonzalez JR, Font A (2015) A decision aid to support informed choices for patients recently diagnosed with prostate cancer: a randomized controlled trial. Cancer Nurs 38(3):E42–E50CrossRefPubMed Chabrera CM, Zabalegui A, Bonet M, Caro M, Areal J, Gonzalez JR, Font A (2015) A decision aid to support informed choices for patients recently diagnosed with prostate cancer: a randomized controlled trial. Cancer Nurs 38(3):E42–E50CrossRefPubMed
9.
go back to reference Isebaert S, Van Audenhove C, Haustermans K, Junius S, Joniau S, De Ridder K, Van Poppel H (2008) Evaluating a decision aid for patients with localized prostate cancer in clinical practice. Urol Int 81(4):383–388CrossRefPubMed Isebaert S, Van Audenhove C, Haustermans K, Junius S, Joniau S, De Ridder K, Van Poppel H (2008) Evaluating a decision aid for patients with localized prostate cancer in clinical practice. Urol Int 81(4):383–388CrossRefPubMed
10.
go back to reference Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, Bhatnagar N, Dahm P, Montori V, Guyatt GH, Tikkinen KAO (2015) Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin 65(3):239CrossRefPubMed Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, Bhatnagar N, Dahm P, Montori V, Guyatt GH, Tikkinen KAO (2015) Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin 65(3):239CrossRefPubMed
12.
go back to reference Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD (2010) Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care 16(5):e121–e130PubMed Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, Ekwueme DU, Thompson IM, Keane TE, Ramsey SD (2010) Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care 16(5):e121–e130PubMed
13.
go back to reference Zeliadt SB, Hannon PA, Trivedi RB, Bonner LB, Vu TT, Simons C, Kimmie CA, Hu EY, Zipperer C, Lin DW (2013) A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak 13(19). https://doi.org/10.1186/1472-6947-13-19 Zeliadt SB, Hannon PA, Trivedi RB, Bonner LB, Vu TT, Simons C, Kimmie CA, Hu EY, Zipperer C, Lin DW (2013) A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak 13(19). https://​doi.​org/​10.​1186/​1472-6947-13-19
14.
go back to reference Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J (2014) The validity of the distress thermometer in prostate cancer populations. Psychooncology 23:195–203CrossRefPubMed Chambers SK, Zajdlewicz L, Youlden DR, Holland JC, Dunn J (2014) The validity of the distress thermometer in prostate cancer populations. Psychooncology 23:195–203CrossRefPubMed
19.
go back to reference O'Connor AM (1995) Validation of a decisional conflict scale. Med Decis Mak 15(1):25–30CrossRef O'Connor AM (1995) Validation of a decisional conflict scale. Med Decis Mak 15(1):25–30CrossRef
20.
go back to reference Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2017) Patient–physician communication and health-related quality of life of patients with localised prostate cancer undergoing radical prostatectomy – a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://doi.org/10.1111/bju.13495 CrossRefPubMed Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2017) Patient–physician communication and health-related quality of life of patients with localised prostate cancer undergoing radical prostatectomy – a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://​doi.​org/​10.​1111/​bju.​13495 CrossRefPubMed
Metadata
Title
Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results
Authors
Brindha Pillay
Daniel Moon
Denny Meyer
Helen Crowe
Sarah Mann
Nicholas Howard
Addie Wootten
Mark Frydenberg
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04847-5

Other articles of this Issue 2/2020

Supportive Care in Cancer 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine